A dose-finding study of the effects of OC000459 on responses to allergen challenge in the Vienna chamber in subjects known to suffer from grass pollen induced allergic rhinitis: a randomised, double-blind placebo-controlled, parallel group evaluation of the dose response curve and minimum effective dose given orally for eight days

Trial Profile

A dose-finding study of the effects of OC000459 on responses to allergen challenge in the Vienna chamber in subjects known to suffer from grass pollen induced allergic rhinitis: a randomised, double-blind placebo-controlled, parallel group evaluation of the dose response curve and minimum effective dose given orally for eight days

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs OC 459 (Primary)
  • Indications Allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Oxagen
  • Most Recent Events

    • 26 Nov 2008 Status changed from recruiting to completed, as reported in ClinicalTrials.gov record.
    • 11 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top